A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori

P Patrick Basu, Krishna Rayapudi, Tommy Pacana, Niraj James Shah, Nithya Krishnaswamy, Molly Flynn, P Patrick Basu, Krishna Rayapudi, Tommy Pacana, Niraj James Shah, Nithya Krishnaswamy, Molly Flynn

Abstract

Objectives: Resistance to standard Helicobacter pylori (HP) treatment regimens has led to unsatisfactory cure rates in HP-infected patients. This study was designed to evaluate a novel four-drug regimen (three antibiotics and a proton pump inhibitor (PPI)) for eradication of HP infection in treatment-naive patients.

Methods: Patients with a diagnosis of HP gastritis or peptic ulcer disease confirmed using endoscopy and stool antigen testing were eligible for inclusion in this study. All patients underwent a washout period of 6 weeks from any prior antibiotic or PPI usage. Patients were then randomized to either levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) therapy for 7 days (LOAD-7) or 10 days (LOAD-10), including levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina) 500 mg twice daily with meals and doxycycline 100 mg at dinner, or lansoprozole, amoxicillin, and clarithromycin (LAC) therapy for 10 days, which included lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner. HP eradication was confirmed by stool antigen testing at least 4 weeks after cessation of therapy.

Results: Intention-to-treat analysis revealed significant differences (P<0.05) in the respective eradication rates of the LOAD therapies (88.9% (80/90) LOAD-10, 90% (81/90) LOAD-7, 89.4% (161/180) for combined LOAD) compared with those receiving LAC, 73.3% (66/90). There were no differences in adverse effects between the groups.

Conclusions: This open-label, prospective trial demonstrates that LOAD is a highly active regimen for the treatment of HP in treatment-naive patients. A large randomized controlled trial is warranted to further evaluate the efficacy of this regimen.

Figures

Figure 1
Figure 1
Comparative efficacy, intent-to-treat analysis. *LAC vs. all LOAD, P=0.0001; LAC vs. LOAD-7, P=0.006; LAC vs. LOAD-10, P=0.013. There was no difference between the LOAD regimens as compared with each other. LAC, lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner; LOAD, levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina®) 500 mg twice daily with meals and doxycycline 100 mg at dinner.
Figure 2
Figure 2
Comparative efficacy, per protocol analysis. *LAC vs. all LOAD, P=0.0003; LAC vs. LOAD-7, P=0.0047; LAC vs. LOAD-10, P=0.0035. There was no difference between the LOAD regimens as compared with each other. LAC, lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner; LOAD, levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina®) 500 mg twice daily with meals, and doxycycline 100 mg at dinner

References

    1. de Vries AC, Kuipers EJ. Helicobacter pylori infection and nonmalignant diseases. Helicobacter. 2010;15 (Suppl 1:29–33.
    1. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among H. pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088–1094.
    1. Houghton JM, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology. 2005;128:1567–1578.
    1. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825.
    1. Egan BJ, Marzio L, O'Connor H, et al. Treatment of Helicobacter pylori infection. Helicobacter. 2008;13 (Suppl 1:35–40.
    1. Gisbert JP, Pajares JM. Helicobacter pylori “rescue” therapy after failure of two eradication treatments. Helicobacter. 2005;10:363–372.
    1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772–781.
    1. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first- and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2008;103:1–5.
    1. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139:463–469.
    1. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95:3393–3398.
    1. Meyer JM, Sillman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.
    1. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321–331.
    1. de Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1999;11:697–700.
    1. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:1921–1930.
    1. Premier Platinum HpSA® PLUS Prescribing Information Meridian Bioscience, Inc. Cincinnati, OH. February 2008.
    1. Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis. Aliment Pharmacol Ther. 1999;13:857–864.
    1. Janssen MJ, Van Oijen AH, Verbeek AL, et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther. 2001;15:613–624.
    1. Gisbert JP, Pajares JM. Treatment of Helicobacter pylori infection: the past and the future. Eur J Intern Med. 2010;21:357–359.
    1. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313–325.
    1. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol. 2010;8:36–41.
    1. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99–107.
    1. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278.
    1. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut. 1997;41:8–13.
    1. Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008;13:56–61.
    1. Loo VG, Sherman P, Matlow AG. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother. 1992;36:1133–1135.
    1. Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47:3260–3269.
    1. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother. 1998;42:2836–2840.
    1. Basu P, Rayapudi K, Esteves J. LEND (levofloxacin, esomeprazole, nitazoxanide and doxycycline) for the treatment of previously non-responsive Helicobacter pylori. Am J Gastroenterol. 2008;103 (suppl 1:S52.
    1. Walker RC. Symposium on antimicrobial agents–part XIII: the fluoroquinolones. Mayo Clin Proc. 1999;74:1030–1037.
    1. Gisbert JP, de la Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35–44.
    1. Di Caro S, Franceschi F, Mariani A, et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis. 2009;41:480–485.
    1. Smilack JD. Symposium on antimicrobial agents–part X: the tetracyclines. Mayo Clin Proc. 1999;74:727–729.
    1. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004;19:789–795.
    1. Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci. 2009;54:599–603.
    1. Sisson G, Goodwin A, Raudonikiene A, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2116–2123.
    1. Yamamoto Y, Hakki A, Friedman H, et al. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity. Chemotherapy. 1999;45:303–312.
    1. Stuppy WP. Dual therapy: nitazoxanide and sucralfate for the treatment of Helicobacter pylori. Am J Gastroenterol. 2010;105 (suppl 1:S45.
    1. Campitelli E, Paszkiewich A, Ibarra D, et al. Efficacy of a nitazoxanide based regimen for Helicobacter pylori eradication. Am J Gastroenterol. 2008;103 (suppl 1:S44.
    1. Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997;11 (suppl 1:21–25.
    1. Vergara M, Vallve M, Gisbert JP, et al. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:647–654.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa